Chen Xiehui, Huang Weichao, Zhao Lingyue, Li Yichong, Wang Lili, Mo Fanrui, Guo Wenqin
Department of Cardiology, Shenzhen Longhua District Central Hospital, Shenzhen, People's Republic of China.
Department of Cardiology, Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen, People's Republic of China.
J Inflamm Res. 2021 Sep 16;14:4687-4696. doi: 10.2147/JIR.S325229. eCollection 2021.
The aim of this study was to assess the value of the eosinophil/monocyte ratio (EMR) for predicting the prognosis of decompensated heart failure (HF).
This was a retrospective cohort study. We included adults (≥18 years old) diagnosed with decompensated HF for whom EMR data were available. The patients were divided into three groups according to EMR tertiles (T1 [EMR≤0.15], T2 [0.15<EMR≤0.32], and T3 [EMR>0.32]). The primary endpoint was the composite outcome of cardiovascular death or HF rehospitalization.
Initially, the records of 2264 patients with decompensated HF were screened; 1883 of these patients had EMR data and were therefore included in the study. There were 627 patients in the T1 group, 628 in the T2 group, and 628 in the T3 group. The risk of cardiovascular death or HF rehospitalization was significantly different among the three groups (Log rank test, P=0.007). Compared with the T3 group, both the T1 group (hazard ratio [HR]: 1.50, 95% confidence interval [CI]: 1.16-1.94, P=0.002) and the T2 group (HR: 1.34, 95% CI: 1.03-1.74, P=0.030) had significantly higher rates of cardiovascular death or HF rehospitalization. A Cochran-Armitage test for trend showed a positive correlation between the EMR and the composite outcome of cardiovascular death or HF. There was a significant difference between the three groups in terms of cardiovascular death (Log rank test, P<0.001) and HF rehospitalization (Log rank test, P=0.03).
The EMR is positively correlated with the risk of cardiovascular death or HF rehospitalization in patients with decompensated HF. Specifically, the lower the EMR, the higher the risk of cardiovascular death or HF rehospitalization.
本研究旨在评估嗜酸性粒细胞/单核细胞比值（EMR）对失代偿性心力衰竭（HF）预后的预测价值。
这是一项回顾性队列研究。我们纳入了年龄≥18岁、诊断为失代偿性HF且有EMR数据的成年人。根据EMR三分位数将患者分为三组（T1组[EMR≤0.15]、T2组[0.15＜EMR≤0.32]和T3组[EMR＞0.32]）。主要终点是心血管死亡或HF再次住院的复合结局。
最初，筛选了2264例失代偿性HF患者的记录；其中1883例患者有EMR数据，因此被纳入研究。T1组有627例患者，T2组有628例患者，T3组有628例患者。三组中心血管死亡或HF再次住院的风险有显著差异（对数秩检验，P = 0.007）。与T3组相比，T1组（风险比[HR]：1.50，95%置信区间[CI]：1.16 - 1.94，P = 0.002）和T2组（HR：1.34，95% CI：1.03 - 1.74，P = 0.030）的心血管死亡或HF再次住院率均显著更高。趋势的 Cochr an - Armitage检验显示EMR与心血管死亡或HF的复合结局之间呈正相关。三组在心血管死亡方面（对数秩检验，P＜0.001）和HF再次住院方面（对数秩检验，P = 0.03）存在显著差异。
EMR与失代偿性HF患者心血管死亡或HF再次住院的风险呈正相关。具体而言，EMR越低，心血管死亡或HF再次住院的风险越高。
